Strategic partnerships PCLabsdx has a history of pursuing partnerships to expand testing capabilities, evidenced by the Amedisys collaboration to bring advanced molecular testing to care centers nationwide. This indicates a sales opportunity to position PCL as a preferred diagnostic partner for home health and community care networks seeking scalable molecular and toxicology testing.

Acquisition footprint The acquisition of Infinity Laboratories in 2022 suggests an active growth strategy and integration capability. A potential sales angle is offering integration services and consolidated reporting/ERP compatibility for US-based lab networks seeking to streamline acquisitions or consolidate multiple labs under a single provider.

Molecular diagnostics focus With emphasis on toxicology, infectious disease, pharmacogenetics, and antibiotic resistance, there is a clear opportunity to target hospitals, clinics, and payer organizations looking to expand precise molecular panels and rapid turnaround times for improved patient outcomes and treatment precision.

Community and wellness tie-ins Past partnerships with fitness centers for drive-up antibody testing show receptivity to on-site or pop-up testing programs. This opens a sales path for occupational health, wellness programs, schools, and event-based testing services that require scalable, convenient diagnostic solutions.

Digital enablement A tech stack including Google Cloud, WordPress/Wix, and reporting platforms points to an opportunity to offer enhanced digital reporting, patient portals, and API integrations with EHR/EMR systems to improve data exchange, analytics, and clinician decision support for prospective buyers.